Solid Biosciences Inc. 8-K

What Happened

• Solid Biosciences (SLDB) filed an 8-K on March 11, 2026 announcing interim results from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 (single IV dose, 1E14 vg/kg) and also made an updated corporate presentation available on its website (Regulation FD disclosure). The clinical data cutoff was February 23, 2026.
• As of March 11, 2026, 40 participants had been dosed across 15 sites in the U.S., Canada, Italy and the U.K. The company reported that SGT-003 has been generally well tolerated using a steroid-only prophylactic immunomodulation regimen. Biopsies were evaluated in 20 participants at Day 90 and 3 participants at Day 360.

Key Details

• 40 participants dosed as of March 11, 2026; safety/tolerability described as generally well tolerated.
• Microdystrophin expression: mean 60% by western blot at Day 90 (n=19) and 91% at Day 360 (n=3); mean microdystrophin-positive fibers by immunofluorescence 63% (Day 90) and 69% (Day 360).
• Biomarker improvements at Day 90 included a 44% mean reduction in eMHC-positive fibers (n=20) and a 38% mean reduction in serum creatine kinase (CK) (n=24); several other serum markers (ALT, AST, LDH, titin) also showed notable mean reductions.
• Regulatory path: FDA agreed with the Phase 3 (IMPACT DUCHENNE) trial design (ambulant participants 7 to <12 years; primary endpoint = change in Time to Rise velocity at 18 months). Company expects to dose the first Phase 3 participant in Q1 2026 and to meet with FDA in H1 2026 about a potential accelerated approval pathway.

Why It Matters

• These interim biopsy and serum biomarker results show clear biological activity (vector delivery, microdystrophin expression and improvements in muscle integrity markers) after a single dose of SGT-003, which is an early indicator the gene therapy is engaging its intended target in Duchenne patients.
• The safety profile reported as “generally well tolerated” and the FDA agreement on the Phase 3 trial design are material near-term developments: Phase 3 dosing expected in Q1 2026 and additional regulatory discussions planned in H1 2026 could be catalysts for the program.
• Important caveats from the filing: the data are interim, sample sizes—especially at Day 360—are small (e.g., n=3 for many 360‑day biopsy measures), and the company notes forward-looking risks (development, manufacturing, regulatory and financing) that could affect outcomes.